Nucala

Active Ingredient(s): Mepolizumab
FDA Approved: * November 4, 2015
Pharm Company: * GLAXOSMITHKLINE LLC
Category: Asthma

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Nucala Overview

Mepolizumab, sold under the brand name Nucala, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis, and hypereosinophilic syndrome (HES).[3] It recognizes and blocks interleukin-5 (IL-5), a signalling protein of the immune system. The most common side effects include headache, injection site reactions, and back pain.[2] Contents 1 Medical uses 2 Side effects 3 Overdose 4 Interactions 5 Pharmacol...

Read more Nucala Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Mepolizumab

Recent Nucala Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Mepolizumab
  • Injection: 100mg, 100mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Nucala: (3 results)

Sorted by National Drug Code
  • 0173-0881 Nucala 100 mg/ml Subcutaneous Injection, Powder, for Solution by Glaxosmithkline LLC
  • 0173-0892 Nucala 100 mg/ml Subcutaneous Injection, Solution by Glaxosmithkline LLC
  • 12064-018 Nucala 100 mg/ml Subcutaneous Injection, Powder, for Solution by Glaxosmithkline Manufacturing Spa

Other drugs which contain Mepolizumab or a similar ingredient: (1 result)